Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 4226 - 4250 of 6046 in total
Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass ▼ Formula
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AM05
  • Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260264 1459.901419 C72H133NO28
Diacylglycerophosphoinositolglycans LMGP15010147
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1,2-dihexadecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM4(16:0/16:0)
126457515 1458.737133 C65H119O33P
Diacylglycerophosphoinositolglycans LMGP15010158
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-octadecanoyl-2-tetradecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM4(18:0/14:0)
126457526 1458.737133 C65H119O33P
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AM07
  • Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260266 1457.885769 C72H131NO28
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AC02
  • Forssman antigen(d18:1/18:0)
  • GalNAcalpha1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260181 1457.860617 C70H127N3O28
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AD02
  • GalNAcbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • Para-Forssman x3b(d18:1/18:0)
44260189 1457.860617 C70H127N3O28
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BC02
  • GalNAcbeta1-3(GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260389 1457.860617 C70H127N3O28
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BD02
  • GlcNAcbeta1-6GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260397 1457.860617 C70H127N3O28
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AC02
  • GalNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260501 1457.860617 C70H127N3O28
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AE02
  • GlcNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260517 1457.860617 C70H127N3O28
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AO02
  • GalNAcbeta1-4(Galbeta1-4GlcNAcbeta1-3)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260597 1457.860617 C70H127N3O28
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AJ02
  • GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260685 1457.860617 C70H127N3O28
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AK02
  • GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • nLc5Cer(d18:1/18:0)
44261053 1457.860617 C70H127N3O28
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BN02
  • GalNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • P antigen(d18:1/18:0)
44261285 1457.860617 C70H127N3O28
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CE02
  • GlcNAcalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261421 1457.860617 C70H127N3O28
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AD02
  • Forssman-like iGb4(d18:1/18:0)
  • GalNAcalpha1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261861 1457.860617 C70H127N3O28
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AO02
  • GalNAcbeta1-3Galalpha1-3(GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261925 1457.860617 C70H127N3O28
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BG02
  • GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261677 1457.860617 C70H127N3O28
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AI04
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44260551 1456.901753 C72H132N2O27
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AC04
  • Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • Lewis a(d18:1/22:0)
44260631 1456.901753 C72H132N2O27
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AD04
  • Fucalpha1-2Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • type I H antigen(d18:1/22:0)
44260639 1456.901753 C72H132N2O27
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AB04
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • Lex-5(d18:1/22:0)
44260983 1456.901753 C72H132N2O27
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AD04
  • Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • type II antigen(d18:1/22:0)
44260999 1456.901753 C72H132N2O27
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AV04
  • Fucalpha1-3GlcNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44261607 1456.901753 C72H132N2O27
Diacylglycerophosphoinositolglycans LMGP15010148
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-hexadecanoyl-2-(9Z-hexadecenoyl)-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM4(16:0/16:1(9Z))
126457516 1456.721483 C65H117O33P

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024